PBYI News and Press, Puma Biotechnology Inc From 05/07/20

Puma Biotechnology (NASDAQ: PBYI ) announces that China's National Medical Products Administration has approved Nerlynx (neratinib) for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, following adjuv...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner CANbridge Pharmaceuticals, Inc. has received marketing approval of NERLYNX® (neratinib) in mainland China from the National Medical Products Administration (NMPA) of China. NERLYNX ...

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will provide an overview of the Company at 3:40 p.m. EDT on Wednesday, May 13, at the BofA Securities Health Care Conference 2020. The conference will be held in a virtual meeting format. A live webcast of the presentat...

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Bixink Therapeutics, a new South Korean company working in the field of anti-cancer drugs and digital therapeutics, have entered into an exclusive agreement under which Bixink will commercialize NERLYNX® (neratinib...

Healthcare stocks, on balance, had a great start to the week today. Cancer companies in particular posted strong gains almost across the board Monday. For instance, the stock of  Clovis Oncology   (NASDAQ: CLVS)  ended the day up by 15.2%, shares of Immunomedics (NASDAQ: IMMU) ...

It's been an exciting time to be an active trader in the market. The emergence of the coronavirus pandemic has sparked a historic wave of volatility which in part reflects the challenge for investors to reconcile the near-term transitory disruptions against potential longer-lasting consequence...

- Will support Sera’s Transition from clinical to commercial stage company - - Sera positioned for growth with several outcome study read-outs taking place in 2020 - SALT LAKE CITY, April 02, 2020 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., The Pregnancy Company...

Investors know that drug development is an expensive and risky endeavor. Most drug candidates fail clinical trials, which is why the direct research and development necessary for each drug candidate that finally makes it to market costs hundreds of millions of dollars. That makes successful drug...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that in connection with the appointment of Jeff Ludwig as Puma’s Chief Commercial Officer, the Compensation Committee of Puma’s Board of Directors approved a grant to Mr. Ludwig of an inducement stoc...

There are a lot of promising stocks out there for investors to choose from. However, if you're looking for companies with the most growth potential, the world of small-cap stocks is one of the best places to look. In particular, biotech stocks are very well known for having tremendous upside ...